IDH1 and glioblastoma: However, several case reports have described prolonged PFS upwards of 15 months following vemurafenib monotherapy in recurrent cases of BRAF V600-mutant glioblastoma,295,296 including a complete response in a paediatric glioblastoma patient.297 Notably, these patients were negative for IDH and EGFR mutations, which may explain the positive response.